PhRMA's new Scientific Leadership Advisory Council is guiding efforts to integrate science into advocacy. The goal is to shift the culture of PhRMA itself and change the conversation on Capitol Hill.
AstraZeneca's third business development model in four years continues to integrate BD into research, and installs an over-arching structure to orchestrate therapeutic strategies from R&D through commercial.
PRODUCT DISCOVERY & DEVELOPMENT
The Partnership to Accelerate Clinical Trials, backed by Bay Area's BioEconomy Initiative, aims to create a centralized IRB across California.
EMERGING COMPANY PROFILE
Alzheon hopes an improved version of a failed beta amyloid aggregation blocker will treat Alzheimer's in APOE4 carriers.
Armo is developing a pegylated form of IL-10 for cancer based on new evidence the former Merck molecule can stimulate an immune response against tumor cells.
FDA Commissioner Margaret Hamburg says FDA, industry and medical practice must change to adapt to rapidly evolving science.
A series of significant financings last week pushed biotech venture rounds across the $5 billion mark in 2013, the 10th straight year in which the industry has crossed this threshold.
BioPacific Investors is looking to inject small amounts of angel capital into U.S. and European companies that have a presence in Asia, or aspire to establish a foothold there.
Ethical finds its diamond. Avalon-GSK go for celiac. Flagship's clinical microbiome play. Also: AB Science; Amarin; Ariad; Biogen Idec; Enanta; Isis; Horizon-Pozen; Oxford Immunotec, et al.